Mount Sinai Medical Center-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2024

  1. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

    New England Journal of Medicine, Vol. 391, Núm. 1, pp. 44-55